Rain Therapeutics (RAIN) has released an update to notify the public and investors about listing compliance status.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company has informed Nasdaq of the completion of a merger, requesting the suspension of trading of its shares from January 26, 2024, and the delisting and deregistration of shares from Nasdaq in accordance with the Securities Exchange Act of 1934. Additionally, the company plans to terminate the registration of the shares and suspend reporting obligations by filing the necessary forms with the SEC.
For further insights into RAIN stock, check out TipRanks’ Stock Analysis page.